Impact of anemia on the outcomes of chronic phase chronic myeloid leukemia in TKI era. Issue 1 (1st January 2020)

• Record Type: Journal Article
• Authors: Liu, Zhenyou; Shi, Yuye; Yan, Zhiling; He, Zhengmei; Ding, Banghe; Tao, Shandong; Li, Yunjie; Yu, Liang; Wang, Chunling
• Is Part Of: Hematology. Volume 25:Issue 1(2020)
• Page Start: 181
• Page End: 185
• Publication Date: 2020-01-01
• Subjects: Chronic myeloid leukemia -- anemia -- hemoglobin level -- survival -- prognosis -- tyrosine kinase inhibitor -- chronic phase -- optimal response; Blood -- Diseases -- Periodicals; Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; 616.15005
• DOI: 10.1080/16078454.2020.1765563
• Languages: English
• ISSNs: 1024-5332

Abstract

ABSTRACT: Objectives: It is common of chronic phase chronic myeloid leukemia (CML-CP) patients coexisting anemia at diagnosis, but the role of anemia on the prognosis is not clear. This study aims to explore impact of anemia on outcomes of CML-CP patients in TKI era. Methods: In the retrospective study, 258 newly diagnosed CML patients treated with TKIs were enrolled. Patients with moderate anemia (Hb ≤ 90 g/L) and non-moderate anemia (Hb > 90 g/L) were compared. Results: The incidence of moderate anemia at the time of CML diagnosis was 34.8%. Compared with patients with non-moderate anemia, patients with moderate anemia had higher proportion of intermediate-high Sokal risks and more aggressive characteristics such as higher WBC counts, higher percent of myeloblasts and basophils. However, there were no statistical differences in terms of optimal response rates, 5-year PFS and OS between the two groups. Conclusion: Moderate anemia is a common concomitant symptom in CML-CP patients and is associated with high-risk CML, but its occurrence does not affect the survival of CML-CP patients in TKI era.